Citigroup Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its target price decreased by analysts at Citigroup from $125.00 to $122.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the healthcare product maker’s stock. Citigroup‘s target price suggests a potential upside of 18.86% from the company’s previous close.

Several other research analysts have also commented on ABT. Robert W. Baird lifted their price objective on shares of Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday. Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday. Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Finally, Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $118.32.

Abbott Laboratories Trading Up 2.1%

ABT traded up $2.13 on Thursday, hitting $102.64. The company had a trading volume of 10,564,601 shares, compared to its average volume of 11,314,207. The business’s fifty day simple moving average is $105.47 and its 200 day simple moving average is $98.28. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The company has a market cap of $177.61 billion, a PE ratio of 33.22, a PEG ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. The business had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the company earned $1.30 EPS. Equities research analysts expect that Abbott Laboratories will post 5.53 EPS for the current year.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently modified their holdings of the stock. Manning & Napier Advisors LLC purchased a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $31,000. Summit Securities Group LLC grew its stake in Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock worth $37,000 after purchasing an additional 118 shares in the last quarter. Addison Advisors LLC bought a new position in Abbott Laboratories in the second quarter worth approximately $40,000. Hoey Investments Inc. increased its holdings in Abbott Laboratories by 59.3% during the 1st quarter. Hoey Investments Inc. now owns 446 shares of the healthcare product maker’s stock worth $46,000 after purchasing an additional 166 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. raised its position in Abbott Laboratories by 221.6% during the 2nd quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker’s stock valued at $43,000 after purchasing an additional 328 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter sales rose 14.5% year over year to $13.01 billion, slightly exceeding estimates, while adjusted EPS of $1.42 matched consensus and improved from $1.30 a year earlier. Abbott also reaffirmed its full-year EPS guidance. Abbott third-quarter results
• Positive Sentiment: Analysts remain constructive despite trimming price targets. Wells Fargo raised its target to $119 and maintained an overweight rating, while RBC, JPMorgan, TD Cowen and BTIG retained positive ratings with targets implying roughly 15%–22% upside. Robert W. Baird also raised its target to $123.
• Positive Sentiment: Abbott received European CE Mark authorization for its Cologuard Plus colorectal cancer screening test, expanding the potential market for its diagnostics business. Cologuard Plus European authorization
• Neutral Sentiment: Abbott plans a tax-free spin-off of its approximately $8.5 billion global Nutrition business into a separate public company by the end of 2027. Management expects the separation to create more focused investment strategies and accelerate Abbott’s sales growth and margins, but execution and valuation remain future uncertainties. Abbott Nutrition spin-off announcement
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing diabetes-related pricing pressure and weakness in parts of its electrophysiology and medical-device portfolio. Investors viewed the guidance reduction as more important than the quarterly revenue beat. Abbott lowers 2026 sales forecast
• Negative Sentiment: India’s food regulator questioned Abbott and Nestlé over infant-formula claims, creating a localized regulatory and reputational risk for Abbott’s Nutrition business. India infant-formula regulatory notice

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.